Laurel Wealth Advisors (North Carolina)’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-1,000
Closed -$1K 684
2020
Q4
$1K Buy
+1,000
New +$2.13K ﹤0.01% 584

Other funds holding BMY.RT

Laurel Wealth Advisors (North Carolina)'s BMY.RT Position: Q1 2021 in Review

Laurel Wealth Advisors (North Carolina) sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,000 shares — an estimated $1K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 1,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
  • Laurel Wealth Advisors (North Carolina)'s Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2021, filed 4 May 2021.